- You are here:
- Home »
- Blog »
- breast cancer »
- Endocrine Therapy for DCIS?
Endocrine Therapy for DCIS?
Endocrine therapy for DCIS is part of the standard treatment plan for women diagnosed with ductal carcinoma in situ. Like all conventional cancer therapies, endocrine therapy comes with possible side effects.
The question then is if the therapy- endocrine therapy- is worth the side effects? The decision of course, must be made by the patient. After all, it is the patient’s body, so the patient must decide.
However, the study linked below found that active monitoring had the same (a little less, actually) short-term safety as endocrine therapy did.
What Treatment Should Women with DCIS Think About?
Mastectomy, lumpectomy, radiation, and endocrine therapy are all conventional or FDA-approved therapies for DCIS. Consider evidence-based but non-conventional therapies such as”
- Nutrition,
- Supplementation and
- Lifestyle therapies
shown to reduce the risk of breast cancer.
I am a long-term cancer survivor. I admit to being biased against therapies that can cause side effects. Please do your homework before undergoing therapy.
Have you been diagnosed with ductal carcinoma in situ aka DCIS? Do you know your risk level? What therapies have you had? Scroll down the page, post a question or comment and I will reply to you ASAP
thank you,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
Key Points
Question What is the short-term safety of an active monitoring approach vs guideline-concordant care (surgery with or without radiation therapy) for hormone receptor–positive, grade 1 or grade 2 breast ductal carcinoma in situ?
Findings In this prospective randomized clinical trial of 957 participants, the 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 5.9% in the guideline-concordant care group vs 4.2% in the active monitoring group, a difference of −1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care.
Meaning These data support the short-term safety of active monitoring compared with guideline-concordant care in patients with low-risk ductal carcinoma in situ.
Abstract
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown.
Objective To compare rates of invasive cancer in patients with low-risk DCIS receiving active monitoring vs guideline-concordant care.
Design, Setting, and Participants Prospective, randomized noninferiority trial enrolling 995 women aged 40 years or older with a new diagnosis of hormone receptor–positive grade 1 or grade 2 DCIS without invasive cancer at 100 US Alliance Cancer Cooperative Group clinical trial sites from 2017 to 2023.
Interventions Participants were randomized to receive active monitoring (follow-up every 6 months with breast imaging and physical examination; n = 484) or guideline-concordant care (surgery with or without radiation therapy; n = 473).
Main Outcomes and Measures The primary outcome was 2-year cumulative risk of ipsilateral invasive cancer diagnosis, according to planned intention-to-treat and per-protocol analyses, with a noninferiority bound of 5%.
Results The median age of the 957 participants analyzed was 63.6 (95% CI, 55.5-70.5) years in the guideline-concordant care group and 63.7 (95% CI, 60.0-71.6) years in the active monitoring group. Overall, 15.7% of participants were Black and 75.0% were White. In this prespecified primary analysis, median follow-up was 36.9 months; 346 patients had surgery for DCIS, 264 in the guideline-concordant care group and 82 in the active monitoring group. Forty-six women were diagnosed with invasive cancer, 19 in the active monitoring group and 27 in the guideline-concordant care group. The 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 4.2% in the active monitoring group vs 5.9% in the guideline-concordant care group, a difference of −1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care. Invasive tumor characteristics did not differ significantly between groups.
Conclusions and Relevance Women with low-risk DCIS randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.
Endocrine therapy for DCIS Endocrine therapy for DCIS Endocrine therapy for DCIS